Development of non-iodinated, non ionic, water-soluble metal based compounds for clinical administration as radiographic contrast media.

开发用于临床施用的非碘化、非离子、水溶性金属化合物作为放射照相造影剂。

• 批准号: DP0557989
• 负责人: Prof Peter Junk
• 金额: $ 20.78万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-04-01 至 2008-07-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0557989
• 关键词: Development; non; iodinated; ionic; water

Every year Australia spends more than $50 million on importing radiographic contrast media, in an international market worth more than $1 billion pa. Existing iodine based agents, which currently cause major adverse reactions in 1% of the population, could be replaced by new metal based imaging media which provide both enhanced contrast and greater patient safety and comfort. Even a small fraction of the international market would generate millions of dollars in overseas income from a range of potential sources, including licensing/royalties to export by a local start-up company, and expansion of rare earth mining in Australia.

澳大利亚每年在进口放射造影剂上花费超过 5000 万美元，而国际市场每年价值超过 10 亿美元。现有的碘基药物目前在 1% 的人口中引起主要不良反应，可以被新型金属基成像介质取代，这种介质既能增强对比度，又能提高患者的安全性和舒适度。即使国际市场的一小部分也能通过一系列潜在来源产生数百万美元的海外收入，包括当地初创公司的出口许可/特许权使用费，以及澳大利亚稀土开采的扩张。